Jason Gould

Mercia Fund Management Ltd. (Mercia Fund) is a private equity subsidiary of Mercia Asset Management Plc founded in 1999 by Mark Andrew Payton, Timothy R. Hazell and Everard Mascarenhas. The firm is headquartered in Warwickshire, Great Britain.

Delta Diagnostics Ltd. develops and provides assays diagnostics solutions. It offers cystic fibrosis, rapid aneuploidy analysis, and genetic disease diagnosis. The company was founded in 1994 and is headquartered in Lancashire, the United Kingdom.

Oxford University Innovation Ltd (Oxford University Innovation) is a venture capital subsidiary of University of Oxford founded in 1987 and spun out in 2010. The firm is headquartered in London, United Kingdom.

Thalia Design Automation Ltd. supplies electronic design automation tools. It offers products and solutions that help engineers overcome the design challenges they face in the increasingly complex worlds of chip design. The company was founded by Sowmyan Rajagopalan in 2011 and is headquartered in Cwmbran, the United Kingdom.

MIP Diagnostic Ltd. develops molecularly imprinted polymers for research purposes, diagnostics and drugs. The company was founded by Sergey Piletsky in 2015 and is headquartered in Leicester, the United Kingdom.

Part of Mercia Asset Management Plc, Mercia Investments Ltd. provides investment services. The company is based in Henley-in-Arden, UK. Founded in 2014.

Enterprise Ventures Group Ltd. provides financing services to small businesses in England and Wales. It offers venture capital, growth capital, and loans to small and medium enterprises. The company was founded in 2001 and is headquartered in Preston, the United Kingdom.

Oxford Genetics Ltd. produces modular DNA plasmids for biological research. Its products include DNA systems, kits, and cell lines. The company was founded by Ryan Cawood and Leonard Seymour on April 28, 2011 and is headquartered in Oxford, the United Kingdom.

PolyTherics Ltd. develops biomedical polymers for therapeutic applications. The company was founded by Antony Godwin, Sunil Shaunak and Steve Brocchini in 2001 and is headquartered in Babraham, the United Kingdom.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

The Native Antigen Co. Ltd. develops viral vectors technologies. Its products include bacterial antigens, protozoal, and viral antigens. The company was founded by Nick Roesen and Andrew Maxwell in 2010 and is headquartered in Oxford, the United Kingdom.

Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage.

Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK.

Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France.

International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium.

Growthdeck Ltd. provides equity investment platform. It offers investors more investment experience transparency to data in the United Kingdom crowdfunding industry. The firm undertakes professional grade due diligence in selecting potential investee companies and offers proper protection for minority shareholders. The company was founded by Gary Robins and James Wrighton and is headquartered in London, the United Kingdom.

Downing Ventures (Downing Ventures) is an independent venture capital firm founded in 1986. The firm is headquartered in London.

Channel Mum Ltd. operates a parental website with editorial content, discussion forums and chats as its main feature. The firm offers information on parenting issues. The company was founded by Siobhan Freegard on November 18, 2014 and is headquartered in London, the United Kingdom.

Imagen Ltd. develops video platform software and video hosting services. Its products include imagen, imagencloud, and orbital. The company was founded by Anthony John Blake and Paul Edward McConkey in 1991 and is headquartered in Cambridge, the United Kingdom.

Foresight Group LLP (Foresight Group) is a private equity subsidiary of Foresight Group CI Ltd founded in 1984 by Bernard William Fairman. The firm is headquartered in London.

Mitsui & Co. Europe Plc (Private Equity) (Mitsui & Co. Europe) is a venture capital firm headquartered in London.

NETRIS Pharma SAS develops targeted therapies for the treatment of cancer. The company is based in Lyon, France. The French company was founded in 2008 by Patrick Mehlen, Agnès Bernet. Patrick Mehlen has been the CEO since 2008.

Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products.

Synergie Lyon Cancer provides health care services. It focuses on research efforts on cancer escape, apoptosis and senescence and Immune surveillance. The company was founded in 2007 and is headquartered in Lyon, France.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.